Trial Profile
A Phase 1, Two Stage, Single-Blind, Single Dose, Placebo Controlled, Dose Escalation, Crossover Study of the Safety and Tolerability of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease Following a Gluten-Containing Meal
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Latiglutenase (Primary)
- Indications Coeliac disease
- Focus Adverse reactions
- Sponsors Alvine Pharmaceuticals
- 15 Oct 2014 New trial record